BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10928135)

  • 1. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.
    Persons DL; Arber DA; Sosman JA; Borelli KA; Slovak ML
    Anticancer Res; 2000; 20(3B):1965-8. PubMed ID: 10928135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
    Coogan CL; Estrada CR; Kapur S; Bloom KJ
    Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional Her 2/neu gene copies in patients with Sézary syndrome.
    Utikal J; Poenitz N; Gratchev A; Klemke CD; Nashan D; Tüting T; Goerdt S
    Leuk Res; 2006 Jun; 30(6):755-60. PubMed ID: 16303179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
    Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
    Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
    Kim GY; Oh YL
    Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer in the 21st century: neu opportunities and neu challenges.
    Schnitt SJ
    Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
    Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
    Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.